Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2012
05/01/2012US8168634 Thiazole derivatives as kinase inhibitors
05/01/2012US8168633 Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase
05/01/2012US8168632 Bicyclic amide derivatives for the treatment of respiratory disorders
05/01/2012US8168631 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity
05/01/2012US8168630 Aminodihydrothiazine derivatives substituted with a cyclic group
05/01/2012US8168629 Analgesic combination of tramadol and meloxicam
05/01/2012US8168628 Conjugated psychotropic drugs and uses thereof
05/01/2012US8168627 Helix 12 directed non-steroidal antiandrogens
05/01/2012US8168626 Benzodiazepine compositions for treating epidermal hyperplasia and related disorders
05/01/2012US8168625 Pharmaceutical composition based on agonist of benzodiazepine
05/01/2012US8168624 lorcaserin hydrochloride; obesity
05/01/2012US8168623 Prodrugs of GABA analogs, compositions and uses thereof
05/01/2012US8168622 β-lactamase-resistant cephalosporin ester compounds and salts of thereof
05/01/2012US8168621 6-substituted estradiol derivatives and methods of use
05/01/2012US8168620 Combination of azelastine and steroids
05/01/2012US8168619 Hormonal composition based on a progestational agent and an oestrogen and use thereof
05/01/2012US8168618 Emulsifying agent
05/01/2012US8168617 Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
05/01/2012US8168616 Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
05/01/2012US8168615 Prodrugs of piperazine and substituted piperidine antiviral agents
05/01/2012US8168614 Boron-containing small molecules as anti-inflammatory agents
05/01/2012US8168610 Bispecific oligonucleotide for the treatment of CNS malignancies
05/01/2012US8168607 Methods of treating eye diseases in diabetic patients
05/01/2012US8168606 RNAi inhibition of alpha-ENaC expression
05/01/2012US8168605 Polymeric oligonucleotide prodrugs
05/01/2012US8168604 Antisense antiviral compounds and methods for treating a filovirus infection
05/01/2012US8168602 Compositions, kits and methods for identification, assessment, prevention and therapy of cancer
05/01/2012US8168599 Composition and method for healing tissues
05/01/2012US8168598 Optimised formulation of tobramycin for aerosolization
05/01/2012US8168597 Method for treating cystic fibrosis
05/01/2012US8168596 Use of cycloartane compounds for treating arthritis
05/01/2012US8168595 Antithrombotic dual inhibitors comprising a biotin residue
05/01/2012US8168587 Combination enzyme replacement and small molecule therapy for treatment of lysosomal storage diseases
05/01/2012US8168583 2-fluoronucleosides
05/01/2012US8168418 Expression of HIV polypeptides and production of virus-like particles
05/01/2012US8168392 Tetrahydrofolate synthetase gene
05/01/2012US8168248 Food intermediate having sequestered phytosteryl esters in a polysaccharide matrix
05/01/2012US8168241 For enhancing physical performance of human, foods
05/01/2012US8168232 Formulations and methods of using nitric oxide mimetics in cancer treatment
05/01/2012US8168222 Amphiphilic polymer-protein conjugates and methods of use thereof
05/01/2012US8168218 Delayed release tablet with defined core geometry
05/01/2012US8168217 Sucrose acetate isobutyrate; cellulose acetate butyrate; solvent; rheology modifier; opioid drug; dosage form and formulation; desirable release kinetics; not susceptible to crushing or powdering; not susceptible to extraction using ethanol or water; abuse deterrence and reduced risk of diversion
05/01/2012US8168212 Topical compositions comprising non-proteogenic amino acids and methods of treating skin
05/01/2012US8168209 Method and composition for administering an NMDA receptor antagonist to a subject
05/01/2012US8168193 Molecules, compositions, methods and kits for applications associated with flaviviruses
05/01/2012US8168187 Nucleic acid and corresponding protein entitled 184P1E2 useful in treatment and detection of cancer
05/01/2012US8168179 Treatment method using anti-PD-L1 antibody
05/01/2012US8168178 Methods and compositions for regulating lymphocyte activity
05/01/2012US8168161 Method to promote oral health in companion animals
05/01/2012US8167866 Drug delivery system for accelerated subcutaneous absorption
05/01/2012CA2719512A1 Polymeric topical compositions
05/01/2012CA2717520C Ketorolac tromethamine compositions for treating or preventing ocular pain
05/01/2012CA2698384C 3-pyridyl enantiomers and their use as analgesics
05/01/2012CA2671470C Powder formulation for valganciclovir
05/01/2012CA2665539C Pyrazolopyrimidines as cyclin dependent kinase inhibitors
05/01/2012CA2660577C Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone
05/01/2012CA2652981C Robust sustained release formulations
05/01/2012CA2627351C Lipophilic vehicle-based dual controlled release matrix system
05/01/2012CA2623332C Carboxamide derivatives as muscarinic receptor antagonists
05/01/2012CA2616177C Imidazolylalkyl-pyridines for the treatment of a sleep disorder
05/01/2012CA2599156C Dosage form containing oxycodone and naloxone
05/01/2012CA2598308C Transdermal systems having control delivery system
05/01/2012CA2556669C Hepatitis c inhibitor peptide analogs
05/01/2012CA2550811C Temperature-stable formulations, and methods of development thereof
05/01/2012CA2545626C Sialogogue, oral composition and food product containing the same
05/01/2012CA2545307C Substituted dihydroquinazolines ii
05/01/2012CA2532648C A stable clozapine suspension formulation
05/01/2012CA2517888C Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
05/01/2012CA2516455C Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
05/01/2012CA2509413C Benzazepine derivatives for the treatment of neurological disorders
05/01/2012CA2497066C Process for the preparation of 13-cis-retinoic acid
05/01/2012CA2493789C Anthranyl derivatives having an anti cholecystokinin activity (anti-cck-1), a process for their preparation, and pharmaceutical use thereof
05/01/2012CA2493402C Novel substituted pyrazolo[1,5 a]-1,3,5-triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same
05/01/2012CA2490722C Novel benzimidazole derivatives
05/01/2012CA2475092C Nanoparticulate compositions having lysozyme as a surface stabilizer
05/01/2012CA2456083C Acylthiols and component thiol compositions as anti-hiv and anti-retroviral agents
05/01/2012CA2455633C Sustained-release therapeutic bioadhesive systems
05/01/2012CA2439928C Bacterial translocation inhibitor and method of inhibiting bacterial translocation
05/01/2012CA2439604C N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation
05/01/2012CA2439408C Use of natural egfr inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth factor receptor
05/01/2012CA2438233C Glucosamine and method of making glucosamine from microbial biomass
05/01/2012CA2438080C Gonococcal proteins and nucleic acids
05/01/2012CA2437579C Preparations and use of an ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester
05/01/2012CA2404212C A process for the preparation of epothilone analogs and intermediates
05/01/2012CA2279555C Amyloid beta protein (globular assembly and uses thereof)
04/2012
04/26/2012WO2012054936A1 Treatment of neurodegenerative disease
04/26/2012WO2012054923A2 Therapeutic nanoparticles with high molecular weight copolymers
04/26/2012WO2012054920A2 Antigen-specific, tolerance-inducing microparticles and uses thereof
04/26/2012WO2012054874A1 Novel macrocyclic inhibitors of hepatitis c virus replication
04/26/2012WO2012054862A2 Agents, compositions, and methods for treating pruritis and related skin conditions
04/26/2012WO2012054831A2 Ready to use ketorolac formulations
04/26/2012WO2012054817A1 Delaying and/ or treating hyperglycemia, including diabetes, with poly(alkyl carboxylic acids)
04/26/2012WO2012054815A1 Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
04/26/2012WO2012054813A1 Novel methods for treating breathing disorders or diseases
04/26/2012WO2012054792A2 Composition and method for immunological treatment of cancer, prevention of cancer recurrence and metastasis, and overcoming immune suppressor cells
04/26/2012WO2012054739A2 Structure-guided identification of binding interactions of human laminin receptor precursor with laminin and identification of compounds that affect binding
04/26/2012WO2012054738A1 Combination of an aminoacyl - trna synthetase inhibitor with a further antibacterial agent for attenuating multiple drug resistance
04/26/2012WO2012054724A1 Methods of treating seizure disorders
04/26/2012WO2012054723A2 Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
04/26/2012WO2012054721A1 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
1 ... 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 ... 7860